Skip to content
Review Open access

Focal Cortical Dysplasia Type II: Somatic Mutations, Molecular Mechanisms, and Integrative Multi‐Omics Framework

Sep 2026 · CNS Neuroscience & Therapeutics · Vol 32 · 0 citations · 81 references
Medicine

TL;DR

FCD II should be considered a mosaic developmental disorder involving both cell‐autonomous and non‐cell‐autonomous mechanisms and integrating somatic variant detection with cellular, spatial, electrophysiological, and surgical outcomes from matched patient tissue may enable biologically meaningful stratification and support the development of novel therapies.

Abstract

ABSTRACT Background Focal cortical dysplasia Type II (FCD II) is a major cause of drug‐resistant epilepsy in children. Somatic mosaic variants affecting the PI3K–AKT–mTOR pathway are implicated in a substantial proportion of cases. The links between genotype, cellular pathology, epileptogenic networks, and clinical outcome remain incompletely defined. Methods This review synthesizes evidence on somatic mTOR–pathway variants, lesion development, pathological cell populations, circuit mechanisms, single‐cell and spatial multi‐omics approaches in FCD II. Results The developmental timing, lineage distribution, and local expansion of somatic variants influence lesion extent and phenotypic heterogeneity. Dysmorphic neurons may contribute to epileptogenicity through altered intrinsic excitability and synaptic function, whereas balloon cells may predominantly affect local circuits through secretory and microenvironmental mechanisms. mTOR hyperactivation may also alter interneuron development, subtype specification, and synaptic connectivity, thereby disrupting excitation‐inhibition balance. Single‐cell and spatial approaches, including RNA velocity, pseudotime analysis, chromatin‐age inference, and somatic genotyping, provide tools to resolve pathological cell states and lineage trajectories. Conclusions FCD II should be considered a mosaic developmental disorder involving both cell‐autonomous and non‐cell‐autonomous mechanisms. Integrating somatic variant detection with cellular, spatial, electrophysiological, and surgical outcomes from matched patient tissue may enable biologically meaningful stratification and support the development of novel therapies.

Read PDF

Similar papers

Review Open access Oct 2026

Balloon cells in type II focal cortical dysplasia: developmental origins, molecular signatures, and epileptogenic mechanisms

Type II focal cortical dysplasia (FCD II) is a major cause of drug-resistant epilepsy in children, with balloon cells representing a defining histopathological feature of FCD IIb. Although diagnostically important, the biological identity and epileptogenic contribution of balloon cells remain incompletely understood. C...

Yan Gao, Xin-Na Ji, Shuo Feng et al. · 0 citations
Review Open access Aug 2026

The genetic architecture of epilepsy across molecular mechanisms and clinical heterogeneity

This review synthesizes contemporary insights into the genetic and molecular pathophysiology of seizures and epilepsy, with emphasis on mechanisms that destabilize excitation–inhibition balance, promote epileptogenesis, and drive pharmacoresistance and supports more refined approaches to epilepsy classification and fut...

Mohammad Reza Seyedtaghia, Jina Babanzadeh, M. Scala et al. · 0 citations
Review Sep 2026

Somatic mosaicism in the brain: linking development, ageing and neurodegeneration.

Emerging data link brain somatic variants to neurodevelopmental and neurodegenerative phenotypes, supporting a unified framework in which mosaic genetics bridges focal lesions and distributed neurological syndromes.

Zi-Nan Zhou, Christopher A. Walsh · 0 citations
Review Open access Sep 2026

Somatic Mosaicism of the Brain: The Functional Implications of Post‐Zygotic Mutations to Neural Circuits

It is concluded that understanding the brain as a dynamic mosaic of billions of distinct genomes—rather than a single‐genome organ—is essential for accurate disease modelling, diagnostics and the development of targeted therapies.

Maher Abdulrazzaq Al-Hakeem, Y. Q. Almajidi, S. Alshkarchy et al. · 0 citations
Review Sep 2026

CNTNAP2 in neurodevelopmental disorders: Genetics, excitation/inhibition mechanisms and preclinical evidence.

This review synthesizes recent genetic, molecular, cellular and preclinical evidence on CNTNAP2 function and dysfunction across the neurodevelopmental spectrum from highly penetrant recessive disorder to common autism spectrum disorder risk variation with the focus on human-specific expression patterns, mechanistic con...

Arpan Dhungel, Rinchi Bora, A. Chamidah et al. · 0 citations
Open access Sep 2026

Pervasive Somatic Mutations in NF1 Drive Cell Type and Spatially Specific Clonal Selection in Neurofibromatosis

Tumorigenesis is a multi-step process shaped by the accumulation of somatic driver mutations, but identifying the earliest steps and cell of origin of tumorigenesis remains challenging. Single cell genomics in >1.7 million single cells across donors with the cancer predisposition syndrome neurofibromatosis type 1 (NF-1...

D. Snellings, Kow Essuman, Benjamin Finander et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.